Evidence map›Paper›PMID 42635941›Full record

ArticleArchives of pharmacal research2026

A novel Skp2 inhibitor triggers pyroptosis in leukemia via phospholipid metabolism disorder and mitochondria-associated endoplasmic reticulum membranes.

Xiaolong Tian, Jiarun Li, Guancui Yang, Peijie Jiang, Xueqing Yang, Shijie Yang, Xi Zhang, Jinyi Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xiaolong Tian *State Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Jiarun Li *State Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Guancui YangState Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Peijie JiangState Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Xueqing YangState Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Shijie YangState Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China.
Xi ZhangState Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China. zhangxxi@sina.com.ORCID http://orcid.org/0000-0002-8548-2832
Jinyi LiuState Key Laboratory of Trauma and Chemical Poisoning, Military Key Clinical Specialty, Chongqing Key Clinical Specialty, Chongqing Key Laboratory of Hematology and Microenvironment, Medical Center of Hematology, Second Affiliated Hospital, Army Medical University, Chongqing, 400037, China. wsliujinyi@163.com.ORCID http://orcid.org/0000-0002-7956-3476

Funding

Chongqing Science and Health Joint medical research project 2024MSXM156National Natural Science Foundation of China 82300196Natural Science Foundation of Chongqing Municipality CSTB2023NSCQ-MSX0262Young Talent Project of Xinqiao hospital 2022YQB062
6 · The paper itself

Abstract

Philadelphia chromosome-positive (Ph

Indexed as

Antineoplastic AgentsEndoplasmic ReticulumLeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMitochondriaPhospholipidsPyroptosisS-Phase Kinase-Associated ProteinsAnimalsCell Line, TumorCell ProliferationCell SurvivalDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansMiceAntineoplastic AgentsPhospholipidsSKP2 protein, humanS-Phase Kinase-Associated ProteinsAAA-237MAMsPh+ leukemiaPhospholipid metabolismPyroptosis

Identifiers

PMID42635941

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.